title: [Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism?].
abstract: BACKGROUND
  A pathophysiological concept of osteoporosis therapy - antiresorptive treatment of high-turnover osteoporosis (e. g. bisphosphonates, raloxifen) and osteoanabolic treatment of low-turnover osteoporosis (e. g. parathyroid hormone) - is clinically and economically reasonable to enable physicians to decide who will benefit most from which drug. Biochemical bone markers in serum and urine are frequently used for the diagnosis of high- or low-turnover osteoporosis. We investigated whether bone marker levels reflect the histologically diagnosed high- or low-turnover state of osteoporosis.
  
  
  METHODS
  175 bone biopsies of male and female osteoporotic patients (WHO criteria) were histologically classified in high- and low-turnover osteoporosis and associated with bone marker levels in serum and urine. Patients with any osteotropic therapy and with fractures were excluded.
  
  
  RESULTS
  There were no significant differences between patients with high- and low-turnover osteoporosis with regards to osteocalcin, DPD crosslinks, alkaline phosphatase, 25-OH vitamin D(3), parathyroid hormone and bone mass (spine and hip).
  
  
  CONCLUSIONS
  Single measurements of biochemical bone markers in serum and urine do not allow a valid differentiation between histologically diagnosed high- and low-turnover states of osteoporosis. The therapeutic concept of treating with osteoanabolic drugs requires valid diagnostic criteria for the differentiation between high- and low-turnover state of bone metabolism which can be provided by a bone biopsy but not by single measurements of bone markers.
authors.affiliation: Sektion Osteologie, Innere Medizin I, Ruprecht-Karls-Universität Heidelberg, Germany.
authors.forename: Beate
authors.initials: B
authors.lastname: Mehl
authors.forename: Günter
authors.initials: G
authors.lastname: Delling
authors.forename: Ingo
authors.initials: I
authors.lastname: Schlindwein
authors.forename: Peter
authors.initials: P
authors.lastname: Heilmann
authors.forename: Christian
authors.initials: C
authors.lastname: Voia
authors.forename: Reinhard
authors.initials: R
authors.lastname: Ziegler
authors.forename: Peter
authors.initials: P
authors.lastname: Nawroth
authors.forename: Christian
authors.initials: C
authors.lastname: Kasperk
mesh_terms: D015502:Absorptiometry, Photon; D015415:Biomarkers / Q000097:blood*; D001707:Biopsy, Needle; D001842:Bone and Bones / Q000473:pathology*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010006:Osteoblasts / Q000473:pathology; D010010:Osteoclasts / Q000473:pathology; D010024:Osteoporosis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D010281:Parathyroid Hormone / Q000627:therapeutic use; D011237:Predictive Value of Tests; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D004164:Diphosphonates; D010281:Parathyroid Hormone; D020849:Raloxifene Hydrochloride